IN2014DN08011A - - Google Patents

Info

Publication number
IN2014DN08011A
IN2014DN08011A IN8011DEN2014A IN2014DN08011A IN 2014DN08011 A IN2014DN08011 A IN 2014DN08011A IN 8011DEN2014 A IN8011DEN2014 A IN 8011DEN2014A IN 2014DN08011 A IN2014DN08011 A IN 2014DN08011A
Authority
IN
India
Prior art keywords
mmp9
functional fragment
binding proteins
gelatinase
immunoglobulin
Prior art date
Application number
Other languages
English (en)
Inventor
Victoria Smith
Scott Mccauley
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of IN2014DN08011A publication Critical patent/IN2014DN08011A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • C12N9/6491Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24035Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486Metalloendopeptidases (3.4.24)
    • G01N2333/96491Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN8011DEN2014 2012-02-29 2012-02-29 IN2014DN08011A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
IN2014DN08011A true IN2014DN08011A (ko) 2015-05-01

Family

ID=45816000

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8011DEN2014 IN2014DN08011A (ko) 2012-02-29 2012-02-29

Country Status (23)

Country Link
US (4) US9550836B2 (ko)
EP (1) EP2820048B1 (ko)
JP (1) JP6067756B2 (ko)
KR (1) KR20140130724A (ko)
CN (1) CN104395345A (ko)
AP (1) AP2014007907A0 (ko)
AU (4) AU2012318302C1 (ko)
BR (1) BR112014021477A2 (ko)
CA (1) CA2865530C (ko)
CL (1) CL2014002282A1 (ko)
CO (1) CO7061040A2 (ko)
CR (1) CR20140443A (ko)
EA (1) EA201491575A1 (ko)
EC (1) ECSP14020504A (ko)
ES (1) ES2731441T3 (ko)
HK (2) HK1205153A1 (ko)
IN (1) IN2014DN08011A (ko)
MD (1) MD20140107A2 (ko)
MX (1) MX2014010449A (ko)
PH (1) PH12014501931A1 (ko)
SG (1) SG11201405305PA (ko)
WO (1) WO2013130078A1 (ko)
ZA (1) ZA201406319B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5878538B2 (ja) 2010-08-27 2016-03-08 ギリアド バイオロジクス, インク.Gilead Biologics, Inc. マトリクスメタロプロティナーゼ9に対する抗体
CA2865530C (en) 2012-02-29 2019-02-19 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
MD20140108A2 (ro) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale
KR20160125466A (ko) * 2014-02-27 2016-10-31 길리애드 사이언시즈, 인코포레이티드 매트릭스 메탈로프로테이나제 9에 대한 항체 및 그의 사용 방법
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985295A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
CN105037553B (zh) * 2015-08-20 2018-04-17 内蒙古蒙元生物基因科技有限公司 一种能够检测癌症的免疫球蛋白
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US10326830B1 (en) * 2016-09-02 2019-06-18 Amazon Technologies, Inc. Multipath tunneling to a service offered at several datacenters
BR112019012253A2 (pt) 2016-12-16 2020-01-28 Centre Hospitalier Univ Bordeaux inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação
WO2018170488A1 (en) 2017-03-17 2018-09-20 Gilead Sciences, Inc. Method of purifying an antibody
KR102657653B1 (ko) 2017-07-18 2024-04-16 다이이찌 산쿄 가부시키가이샤 활성형 mmp-9 결합 펩티드
CN110885375B (zh) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
CN111785321B (zh) * 2020-06-12 2022-04-05 浙江工业大学 一种基于深度卷积神经网络的dna绑定残基预测方法
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ES2327812T3 (es) * 1999-07-13 2009-11-04 University Of Southern California Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
CN1459505A (zh) * 2002-05-21 2003-12-03 赵平 中国汉族人基质金属蛋白酶-9基因重构、表达、纯化及其医学应用
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体成分c5に対する抗体を使用する喘息の処置の方法
US8957187B2 (en) * 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
WO2008154439A1 (en) * 2007-06-08 2008-12-18 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
EP2262529A4 (en) * 2008-03-03 2013-05-08 Dyax Corp METALLOPROTEINASE BINDING PROTEINS 9
CA2717803A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
AU2009308369A1 (en) * 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
CA2787311C (en) * 2010-01-27 2017-08-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
JP5878538B2 (ja) 2010-08-27 2016-03-08 ギリアド バイオロジクス, インク.Gilead Biologics, Inc. マトリクスメタロプロティナーゼ9に対する抗体
MD20140108A2 (ro) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale
CA2865530C (en) 2012-02-29 2019-02-19 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
HK1208036A1 (en) 2016-02-19
ECSP14020504A (es) 2015-09-30
AU2017216508A1 (en) 2017-08-31
US20150140580A1 (en) 2015-05-21
US20190127486A1 (en) 2019-05-02
CR20140443A (es) 2014-11-17
WO2013130078A1 (en) 2013-09-06
CA2865530A1 (en) 2013-09-06
US20170183421A1 (en) 2017-06-29
AU2015242967A1 (en) 2015-11-05
AU2017216508B2 (en) 2019-03-07
HK1205153A1 (en) 2015-12-11
JP2015514394A (ja) 2015-05-21
AU2012318302C1 (en) 2017-06-15
EP2820048A1 (en) 2015-01-07
AU2012318302A1 (en) 2013-09-19
AU2015242967B2 (en) 2017-08-24
AU2012318302B2 (en) 2016-08-18
ZA201406319B (en) 2016-02-24
KR20140130724A (ko) 2014-11-11
CA2865530C (en) 2019-02-19
CN104395345A (zh) 2015-03-04
CO7061040A2 (es) 2014-09-19
US11634505B2 (en) 2023-04-25
AP2014007907A0 (en) 2014-08-31
CL2014002282A1 (es) 2015-02-20
AU2017261626A1 (en) 2017-12-07
ES2731441T3 (es) 2019-11-15
US9550836B2 (en) 2017-01-24
SG11201405305PA (en) 2014-09-26
EA201491575A1 (ru) 2015-01-30
US20210054101A1 (en) 2021-02-25
US10800857B2 (en) 2020-10-13
EP2820048B1 (en) 2019-04-17
MD20140107A2 (ro) 2015-03-31
PH12014501931A1 (en) 2014-11-24
MX2014010449A (es) 2015-02-10
BR112014021477A2 (pt) 2018-06-12
JP6067756B2 (ja) 2017-01-25
NZ629888A (en) 2017-02-24

Similar Documents

Publication Publication Date Title
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
IN2014DN08011A (ko)
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
PH12014502527A1 (en) St2 antigen binding proteins
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
IN2014DN03451A (ko)
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201492101A1 (ru) Антитела против fcrn
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201291065A1 (ru) Антитела против vla-4
EA201590918A1 (ru) Антитела к bmp-6
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
EA201491724A1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
EA201792576A1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения
CL2010000521A1 (es) Anticuerpo aislado o fragmento que bloquea la fijacion de la union de la proteina wise; secuencias de cdr de la cadena liviana y pesada; polipeptido inmunogenico de wise; composicion farmaceutica que comprende dicho anticuerpo.